BioStem Technologies, Inc.
- BSEM
- NASDAQ
- Biotechnology
- Placental Allografts (Wound Care)
- Regenerative Therapies
$1.80
Today −13.88%Quote Oct 19, 2026, 04:07 PM UTC
−52.06%over the last month
Max drawdown −57.0%From 1-month high −55.9%3 months −46.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About BioStem Technologies
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Where the money comes from
Q2 2026 revenue $7.9M
- Hospital$6.7M85.0%
- Other$88,5601.1%
- Other / not reported$1.1M13.9%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
73
Founded
2006
Market value
$33.6M
Quote Oct 19
Analyst target
$7.00
+288.9% from here
Resistance
$1.81
0.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BSEMPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free